Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells
Kenjiro Suzuki,Ryuichi Mizuno,Kiyotake Suenaga,Toshiaki Teruya,Nobuyuki Tanaka,Takeo Kosaka,Mototsugu Oya +6 more
TLDR
Bisebromoamide is a promising potential agent against RCC due to its ability to inhibit both the Raf/MEK/ERK and PI3K/Akt/mTOR pathways.Abstract:
Advanced renal cell carcinoma (RCC) remains an incurable disease, and newer anticancer drugs are needed. Bisebromoamide, a novel cytotoxic peptide, was isolated from the marine cyanobacterium Lyngbya species at our laboratory in 2009. This compound specifically inhibited the phosphorylation of ERK in platelet-derived growth factor-activated normal rat kidney cells. The aim of this study was to evaluate the effect and elucidate the potential mechanism of Bisebromoamide actions on human RCC cells. Two renal cancer cell lines, 769-P and 786-O, were used. The effects of Bisebromoamide were analyzed employing assays for water-soluble Tetrazolium-1 salts. Apoptosis was determined by flow cytometric TUNEL analysis. Cell-cycle distributions were analyzed by flow cytometry using BrdU/propidium iodide (PI) staining. Kinases of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of Rapamycin (mTOR) pathway and Raf/MEK/ERK pathway were analyzed by Western blotting. After Bisebromoamide treatment for 48 and 72 h, cell viability was significantly decreased in both cell lines at 1 and 10 μmol/L. After treatment with 1 μmol/L Bisebromoamide for 72 h, apoptosis and the increased percentage of cells in the sub-G1 phase were observed in both cell lines. Bisebromoamide inhibited the phosphorylation of ERK and Akt in both cell lines tested. Similar effects were demonstrated for phosphorylation of mTOR and p70 S6. Bisebromoamide is a promising potential agent against RCC due to its ability to inhibit both the Raf/MEK/ERK and PI3K/Akt/mTOR pathways.read more
Citations
More filters
Journal ArticleDOI
Mitogen-Activated Protein Kinases and Hypoxic/Ischemic Nephropathy.
TL;DR: Current evidence indicates that a reduction in renal oxygen tension/blood supply plays an important role in acute kidney injury, chronic kidney disease, and renal tumorigenesis, and recent studies suggest that these MAPKs are differentially involved in renal responses to hypoxic/ischemic stress.
Journal ArticleDOI
Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy.
TL;DR: This review focuses on marine compounds that target the PI3K/Akt signaling pathway for the prevention and treatment of cancer and provides comprehensive information for those interested in research on marine drugs.
Journal ArticleDOI
Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics.
Piyush Baindara,Santi M. Mandal +1 more
TL;DR: The anticancer properties and mechanism of actions of the anticancer agents of bacterial origin and antitumor bacteria along with their possible future applications in cancer therapeutics are summarized.
Journal ArticleDOI
Recent Advances in Small Peptides of Marine Origin in Cancer Therapy.
TL;DR: This paper highlights the anticancer linear and cyclic small peptides in marine resources and presents a review of peptides and the derivatives and their mechanisms.
Journal ArticleDOI
Cyanobacteria as Natural Therapeutics and Pharmaceutical Potential: Role in Antitumor Activity and as Nanovectors
TL;DR: A review of the anti-cancerous cyanobacterial bioactive compounds, along with recently introduced nanomaterials that could be used for the development of new anticancer drugs to build a healthy future for mankind is provided in this article.
References
More filters
Journal ArticleDOI
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer,Bernard Escudier,Stéphane Oudard,Thomas E. Hutson,Camillo Porta,Sergio Bracarda,Viktor Grünwald,John A. Thompson,Robert A. Figlin,Norbert Hollaender,Gladys Urbanowitz,William Berg,Andrea Kay,David Lebwohl,Alain Ravaud +14 more
TL;DR: Treatment with everolimus prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on other targeted therapies, but were mostly mild or moderate in severity.
Journal ArticleDOI
PI3K: Downstream AKTion Blocks Apoptosis
TL;DR: Results from Evan and colleagues demonstrated that mutants of V12 Ras that selectively stimulate PI3K and Akt/PKB but not the Raf/MEK/MAPK pathway are able to prevent c-myc-induced cell death in Rat-1 cells and granule neurons.
Journal ArticleDOI
The protein kinase B/Akt signalling pathway in human malignancy.
TL;DR: Recent developments in understanding the mechanisms and consequences of PKB/Akt activation in human malignancy are surveyed.
Journal ArticleDOI
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.
TL;DR: The role of protein-protein interactions in the regulation of this pathway is focused on, and how they contribute to co-ordinate activation steps, subcellular redistribution, substrate phosphorylation and cross-talk with other signalling pathways.
Journal ArticleDOI
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo,Li Ma,Li Ma,Li Ma,Julie Teruya-Feldstein,Federico Rojo,Leonardo Salmena,Leonardo Salmena,Andrea Alimonti,Andrea Alimonti,Ainara Egia,Ainara Egia,Atsuo T. Sasaki,George Thomas,Sara C. Kozma,Antonella Papa,Antonella Papa,Caterina Nardella,Caterina Nardella,Lewis C. Cantley,José Baselga,Pier Paolo Pandolfi,Pier Paolo Pandolfi +22 more
TL;DR: MAPK activation as a consequence of mTORC1 inhibition is identified and the potential of a combined therapeutic approach with m TORC1 and MAPK inhibitors, currently employed as single agents in the clinic, for the treatment of human cancers is underscore.